Olema Pharmaceuticals, Inc.
OLMA
$5.59
-$0.17-2.95%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -10.38% | -4.65% | -19.39% | 13.01% | 22.40% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 12.93% | 18.86% | 10.69% | 61.17% | 55.22% |
Operating Income | -12.93% | -18.86% | -10.69% | -61.17% | -55.22% |
Income Before Tax | -44.11% | 1.88% | -25.38% | -60.71% | -51.19% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -44.11% | 1.88% | -25.38% | -60.71% | -51.19% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -44.11% | 1.88% | -25.38% | -60.71% | -51.19% |
EBIT | -12.93% | -18.86% | -10.69% | -61.17% | -55.22% |
EBITDA | -12.85% | -18.78% | -10.64% | -61.39% | -55.50% |
EPS Basic | 5.13% | 36.17% | -4.40% | -26.21% | -9.38% |
Normalized Basic EPS | 26.79% | 23.90% | 5.48% | -26.24% | -9.40% |
EPS Diluted | 5.13% | 36.17% | -4.40% | -26.21% | -9.38% |
Normalized Diluted EPS | 26.79% | 23.90% | 5.48% | -26.24% | -9.40% |
Average Basic Shares Outstanding | 51.91% | 53.72% | 20.10% | 27.32% | 38.22% |
Average Diluted Shares Outstanding | 51.91% | 53.72% | 20.10% | 27.32% | 38.22% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |